Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11 (biosimilar- ranibizumab)
Shots:
- EMA has accepted to review the MAA for SB11- a proposed biosimilar referencing Lucentis (ranibizumab). If approved- SB11 will join a growing number of biosimilars developed by Samsung Bioepis and commercialized by Biogen
- In Nov 2019- Samsung Bioepis announced that it entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates: SB11 (ranibizumab) and SB15 (aflibercept) in the US- Canada- Europe- Japan- and Australia
- Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders- which are a leading cause of blindness
Ref: BIOGEN | Image:Biogen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com